“We are increasing our investment in vaccines, and we will develop a seasonal flu vaccine, given the unmet need for highly effective vaccines,” CEO Stephane Bancel said in a news release.
The drugmaker said vaccines typically reduce the risk of getting the flu by 40 percent to 60 percent and that high-risk groups would benefit from a flu shot with higher efficacy.
Between 9 million and 45 million people in the U.S. have died of the flu annually since 2010, according to the CDC.
Read the full news release here.
More articles on pharmacy:
Drug costs surge faster than any other medical good or service, data shows
Eli Lilly, Amgen partner to make Lilly’s COVID-19 antibody drug
Moderna will know if COVID-19 vaccine is effective in November, CEO says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.